Ardelyx

Ardelyx, Inc. is a biopharmaceutical company. engages in the research, development and commercialization of medicine for the treatment of cardiorenal diseases. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Ardelyx reports sales growth, readies XPHOZAH launch amid challenges

Ardelyx showed strong sales growth for IBSRELA and is poised for the XPHOZAH launch
Financially, the company raised significant funds and maintains a healthy cash position
Challenges include managing expenses and improving profitability amidst losses
Opportunities lie in upcoming product launches and optimizing financial operations

Ardelyx reports strong Q2 performance amidst legislative challenges and growth opportunities

Ardelyx's Q2 performance reflects growth in IBSRELA sales and overall revenue, despite incurring a net loss.
The company faces challenges from pending legislation and financial burdens related to XPHOZAH launch preparation.
Opportunities lie in the potential of XPHOZAH launch, market reception of IBSRELA, and addressing legislative impacts.

Ardelyx reports strong Q3 earnings, poised for successful XPHOZAH launch

Ardelyx's Q3 performance reflects financial strength and positive market reception for IBSRELA.
Challenges in pricing strategy and market competition require strategic planning for XPHOZAH's launch.
Opportunities lie in leveraging financial stability, physician interest, and promotional activities for XPHOZAH success.
The company's commitment to patient access and learnings from IBSRELA will drive future growth and market penetration.

Ardelyx reports strong revenue growth driven by IBSRELA success

Ardelyx is strategically investing in growth, focusing on sustaining momentum for its products. The company is well-resourced and optimistic about the future performance of IBSRELA and XPHOZAH. Despite challenges in operating expenses, Ardelyx remains committed to its commercialization efforts.

Ardelyx reports robust Q1 performance driven by XPHOZAH success

Ardelyx's Q1 2024 earnings call showcased strong revenue growth, particularly driven by XPHOZAH and IBSRELA. The company's cash position remains healthy, and there is a clear focus on expanding market reach and driving adoption of key therapies.

Ardelyx reports robust Q2 earnings, focuses on patient access advocacy

Ardelyx's Q2 2024 performance reflects strong revenue growth driven by IBSRELA and XPHOZAH, with a focus on shareholder value and patient access advocacy. While facing challenges in legal battles and expense management, the company is poised to capitalize on opportunities through sales force expansion and market differentiation strategies.

Ardelyx (ARDX) reports robust Q3 earnings, navigates Medicare coverage challenges

Ardelyx's Q3 earnings call highlighted strong financial performance, success of key medications, and strategies to address Medicare coverage challenges. The company's focus on patient access, commitment to therapy availability, and positive market impact showcase its growth potential and resilience in the market.

Ardelyx reports robust Q4 earnings driven by IBSRELA and XPHOZAH

Ardelyx's Q4 2024 earnings call highlighted strong financial performance driven by IBSRELA and XPHOZAH, with total revenues of $116.1 million for the quarter. The company emphasized patient benefits, access commitment, and strategic sales force expansion. Analyst inquiries focused on revenue guidance, reimbursement dynamics, and strategies for achieving sales goals and patient access.

Ardelyx reports strong Q1 earnings, faces Medicare coverage challenge

Ardelyx's Q1 2025 earnings call highlighted robust revenue growth driven by IBSRELA and XPHOZAH. While facing challenges like Medicare Part D coverage loss, the company's strong financial position and product performance offer growth opportunities. Optimizing pricing strategies, managing expenses, and exploring new market avenues will be key for Ardelyx's future success.

Ardelyx excels in Q2 with strong revenue growth and product performance

Ardelyx's Q2 2025 performance reflects robust revenue growth driven by strong sales of IBSRELA and XPHOZAH. The company's strengthened leadership team and raised revenue guidance underscore confidence in future growth prospects. While facing challenges such as CFO transition and operational hurdles, Ardelyx is well-positioned to capitalize on opportunities for further expansion. By focusing on top-line growth, cost management, and strategic initiatives, Ardelyx aims to maximize shareholder value and sustain its growth trajectory.

Ardelyx excels in Q3 with record revenue and strategic growth plans

Ardelyx delivered strong financial performance in Q3 2025, driven by robust revenue growth and commercial success of IBSRELA and XPHOZAH. The company's focus on expanding opportunities for growth, introducing new products like ARDX-10531, and maintaining financial strength positions it well for future success in the pharmaceutical market.

Ardelyx excels in 2025 with strong revenue growth and strategic focus

Ardelyx had a stellar year in 2025, achieving strategic milestones and strong revenue growth across key products. The company's focus on patient access, portfolio expansion, and financial strength sets a solid foundation for future growth. While facing challenges in revenue targets and profitability, Ardelyx is well-positioned to capitalize on growth opportunities and drive innovation. Strategic investments in R&D and capital allocation underscore Ardelyx's commitment to sustainable growth and long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.